Biotech Deal Volume Increases 58% in Q3:16

Overall, mergers and acquisitions slowed in Q3:16, down 11% compared with Q2:16, and 10% lower than in Q3:15. The biotechnology sector saw just the opposite phenomenon. Biotech transactions grew by 58%, to 52 deals, compared with the previous quarter’s 33 deals, and by 24% compared with the same quarter in 2015, when 42 deals were announced.  Not all deals in this sector involve the purchase of an entire company, however. Just 42% of the third-quarter transactions fit that description. The remaining 58% deals involved the purchase of exclusive rights and licenses to products, product candidates or intellectual property from a biotech firm. Pharmaceutical companies have pulled back (or... Read More »